Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cancer Biomark. 2010;8(4-5):231-51. doi: 10.3233/CBM-2011-0212.
Epithelial ovarian cancer (EOC) remains the most lethal gynecological malignancy despite several decades of progress in diagnosis and treatment. Taking advantage of the robust development of discovery and utility of prognostic biomarkers, clinicians and researchers are developing personalized and targeted treatment strategies. This review encompasses recently discovered biomarkers of ovarian cancer, the utility of published prognostic biomarkers for EOC (especially biomarkers related to angiogenesis and key signaling pathways), and their integration into clinical practice.
尽管在诊断和治疗方面取得了几十年的进展，但上皮性卵巢癌 (EOC) 仍然是最致命的妇科恶性肿瘤。利用发现和应用预后生物标志物的快速发展，临床医生和研究人员正在开发个性化和靶向治疗策略。本文综述了最近发现的卵巢癌生物标志物、已发表的 EOC 预后生物标志物的实用性（特别是与血管生成和关键信号通路相关的生物标志物）及其在临床实践中的整合。
